The published long-term data suggests that the treatment could maintain its dominant position in the CF market.

Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable ...

Sarepta Therapeutics, Inc. , the leader in precision genetic medicine for rare diseases, today reported new results from Study 9001-103. Also known as ENDEAVOR, Study 9001-103 is a multi-cohort study ...

A 60-year-old woman presents with refractory hypertension and psychosis, revealing a rare adrenal cortical carcinoma — an ...

Since bilirubin often appears in the urine when ... in that it gave rise to 27 false-positive reactions in a total of 1343 tests, an incidence of 2 per cent (Table 2). In all but 2 cases these ...

Ibrahim Ali Khan revealed his childhood speech struggle due to jaundice-induced hearing loss. He continues speech therapy, ...

Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile ...

The Labcorp Liver Health Test measures seven markers: bilirubin, total protein, albumin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase and platelets.

Gilead Sciences, Inc. today announced new data from multiple analyses which reinforce that Livdelzi® (seladelpar), known as Lyvdelzi® in the European Union, is effective and generally well-tolerated ...

Auryxia net product revenues were $43.8 million in the first quarter of 2025 as compared to $31.0 million in the first ...